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To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed
tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to
accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.
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Lung cancer kills more people worldwide than other malignancy.
The number of deaths in the western world has fallen in the past
years and this is likely to be due to a greater public awareness as
well as successes in smoking cessation programmes. Unfortunately,
the tobacco epidemic is still growing in Southeast Asia and China as
the tobacco industry has now concentrated its sales in these
regions. However, there is now a large ex-smoking population in
the United States and Europe, who remain at a very high risk of
developing lung cancer, which is dependent on their smoking
duration before tobacco cessation. This group of individuals now
exceeds current smokers in both the United States and Europe and
will continue to do so over the next two to three decades. National
health-care programmes would have a responsibility, if there were a
proven screening tool, to provide a mechanism by which these
high-risk individuals are identified and targeted for lung cancer
screening. Screening must be instigated before patients develop any
symptoms, as surgical resection at an early stage of the disease
remains the only realistic option for a cure.
CHEST X-RAY AND SPUTUM CYTOLOGY LUNG
CANCER SCREENING
The earliest lung screening trial was undertaken in London with
over 55000 individuals randomised to chest X-ray every 6 months
for 3 years or chest X-ray at the beginning and end of the 3-year
period (Brett, 1969). No mortality difference was found between
the two groups. Three major trials in the United States and one in
Czechoslovakia were developed in the 1970s, as outlined in Table 1.
The results of these large trials were disappointing as none of these
studies showed any reduction in lung cancer mortality utilising
chest X-ray, with or without, sputum cytology. However, some
design features of these trials have been criticised on the basis of
active early detection measures in the control arm in many of the
studies, possible suboptimal selection of study populations, and of
arguably inadequate sample sizes (Prorok et al, 2000). Many of
these criticisms have now been taken on board by the current lung
cancer screening trials.
One current trial, which has ‘usual care’ only in the control arm,
is the lung component of the NCI PLCO (Prostate, Lung Colorectal
and Ovarian) screening trial. In this trial, smokers are offered
annual chest X-ray for 3 years, and non-smokers two annual repeat
screens; the results of this study are not expected until 2010.
LOW-DOSE COMPUTED TOMOGRAPHY LUNG
CANCER SCREENING: OBSERVATIONAL STUDIES
Low-dose computed tomography (LDCT) offers a major advance
in imaging technology, which was first introduced in the 1990s
(Naidich et al, 1990) and later by Reeves and Kostis (2000). This is
more sensitive than chest X-ray and has enabled the detection of
lung tumours less than 1cm; thus, allowing a complete scan on the
thorax in less than 30s. Randomised trials of this technology as a
screening tool have not as yet been completed, but there have been
a number of demonstration projects (Table 2). Early studies of
note include the Early Lung Cancer Action Project (ELCAP)
(Henschke et al, 1999) in 1000 high-risk smokers; the Mayo Clinic
Project with 1520 individuals aged 50 years having annual sputum
cytology and spiral CT screening (Swensen et al, 2000); and a
3-year mass screening programme using a mobile CT unit in Japan
(Sone et al, 1998).
The ELCAP study enroled 1000 symptom-free individuals aged
60 years or more with 410 pack-years history of smoking, who
were fit to undergo surgery into a study. All individuals underwent
an annual spiral CT and chest X-ray. The lung cancer detection rate
was 2.7% in the first year and 0.7% in the second year (incidence),
and this study also demonstrated that the sensitivity of low-dose
spiral CT for early lung cancer was far greater than for chest X-rays.
The majority of ‘screen-detected’ tumours were at an early stage
and suitable for surgery. This seminal paper by Henschke and co-
workers (Henschke et al, 1999) re-ignited interest and debate in
developing new lung cancer screening trials in the United States
and Europe. Other demonstration projects found similar results
(Table 2). The Early Lung Cancer Action Project has since been
expanded to a major international collaboration, I-ELCAP, with
more than 30000 screenees (see below), with similar findings to the
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Lung cancer
screening trial Trial design
No. of
participants
Lung cancer
detected
Lung cancer
mortality
a Reference
London Chest X-ray, 6 months, 3 years 29723 132 2.1 Brett (1969)
vs chest X-ray only at the end of year 3 25311 96 2.4
MSKCC Lung
Cancer Screening
A chest X-ray and sputum cytology,
every 4 months
4968 144 2.7 Melamed et al (1984)
Programme vs chest X-ray annually 5072 144 2.7
Johns Hopkins
Lung Project
A chest X-ray and sputum cytology every
4 months
5226 202 3.4 Frost et al (1984)
vs chest X-ray annually 5161 206 3.8
Mayo Lung
Project
Chest X-ray and sputum cytology every 4 months,
6 years
4618 160 3.9 Marcus et al (2000)
vs chest X-ray and sputum cytology annually 4593 39 3.6
Czechoslovakia Chest X-ray and sputum cytology every 6 months,
3 years
3172 39 3.6 Kubik et al (2000)
vs chest X-ray and sputum cytology beginning of
first year and the end of third year
3174 27 2.6
PLCO Lung aspect of trial: chest X-ray: smokers had test at
the entry and annually for 3 years. Never smokers
had the test at the entry and annually for 2 years
77469 Not published Gohagan et al (2000)
vs usual care 77468
PLCO¼Prostate, Lung Colorectal and Ovarian.
aPer 1000 person-years.
Table 2 LDCT lung cancer screening in observational studies
Reference No. of participants Smokers (PKS) No. of non-calcified nodules No. of lung cancers
Henschke (2000) 1000 Smokers 233 27
PYS 410 63 (incidence) 7 (incidence)
Asbestos 14%
Sone et al (1998) 5483 Smokers B50% 279 22
PYS 41
Swensen et al (2002) 1520 Smokers 2244 25
PYS 420 588 (incidence) 10(incidence)
Sobue et al (2002) 1611 Smokers B85% 186 14
PYS 50% 721 (incidence) 8 (incidence)
Tiitola et al (2002) 602 Smokers 495% 111 5
PYS410
Asbestos 100%
Nawa et al (2002) 7956 Smokers 460% 2865 41
PYS¼50%
Diederich et al (2002) 817 Smokers 100% 858 12
PYS 420 174 (incidence) 10 (incidence)
MacRedmond et al (2004) 449 Smokers 100% 155 2
PYS 410
Asbestos 7.6%
Stephenson et al (2005) 87 Smokers 100% 4
PYS 420
Chong et al (2005) 6406 Smokers 100% 2255 11
PYS 420
Henschke et al (2006) 31567 Smokers ND 484
PYS 15–40
LDCT¼low-dose computed tomography; ND¼not determined; PKS¼pack years; PYS¼pack-years. Table is adapted from Rossi et al (2005) and Yau et al (2007).
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estimated a very high case survival rate for stage I tumours
undergoing surgery. There is, however, considerable debate around
the interpretation of increased survival in LDCT-diagnosed cancers,
as longer survival does not necessarily equate to reduced mortality
(Twombly, 2007). In addition to concerns about self-selection for
surgery (or for no surgery) among stage 1 patients, the major
reservation relates to overdiagnosis of tumours, which would not
have been life threatening and would never have come to clinical
attention in the absence of screening. The previous generation of
chest X-ray trials suggested a measure of overdiagnosis (Kubik
et al, 2000; Marcus et al, 2000). The much greater sensitivity of
LDCT has, in turn, led to fears of an increased risk of overdiagnosis.
The most balanced arguments to date concerning the IELCAP
findings have been in a recent BMJ editorial (McMahon and
Christiani, 2007). The authors’ view is that the objective of lung
cancer screening is to reduce lung cancer mortality, and it is not
possible to confidently conclude this from the IELCAP study.
The one other large observational analysis is by Bach et al (2007)
whose conclusions were diametrically opposed to those from by
the IELCAP Consortium. Bach and colleagues used data from 3246
current or former smokers who entered into screening studies in
the United States and in Italy, with follow-up for a median of 3.9
years. They used a model of predicted risk of lung cancer mortality
to estimate the expected numbers of lung cancer deaths and
compared these with the corresponding observed deaths; they
found no decrease in the number of diagnoses of advanced lung
cancers or deaths from lung cancer (38 deaths due to lung cancer
observed and 38.8 expected; RR 1.0; 95% CI: 0.7–1.3; P¼0.90).
The authors concluded that there was no evidence of a mortality
advantage with LDCT screening from this study. However, their
exclusion of deaths from tumours diagnosed early in the period of
observation has been criticised, as have been various other
assumptions and procedures in their approach.
LDCT LUNG CANCER SCREENING: RANDOMISED
TRIALS
The EU-US spiral CT Collaboration was initiated in 2001 in
Liverpool. Subsequent meetings throughout Europe resulted
in the development of collaborative protocols on radiology,
pathology, minimum datasets, treatment, as well as core LDCT
protocol. This provided a mechanism by which the different
trial groups could work together with the ultimate aim to
pool their data, thereby enhancing the overall power of
these studies and potentially reporting earlier; the concept
of which was formulated in the ‘Liverpool Statement 2005’
(Field et al, 2006).
The randomised trials of LDCT are summarised in Table 3. The
first major RCT lung cancer screening trial utilising LDCT was the
National Lung cancer Screening Trial (NLST), which is a
combination of two trials, one set up by the US National Cancer
Institute (NCI) and the other by the American College of Radiology
Imaging Network (ACRIN). The NLST started in 2002 and
completed enroling in 2004. This study has over 50000 former
and current smokers randomised to annual LDCT or annual
chest X-ray for 3 years. The major objective of this was to
determine whether LDCT reduces lung cancer mortality compared
with a chest X-ray arm. (http://www.cancer.gov/NLST). This
trial will be completed in 2009 and aims to report in 2012; it is
designed to have a 90% power to detect a mortality reduction
of 20%.
The NELSON trial was launched in 2003 in the Netherlands and
Belgium (van Iersel et al, 2007), and now incorporates centres in
Denmark. This trial is designed to compare lung cancer mortality
in a group randomised to LDCT screening with a control group,
without screening. This trial aims to report in 2014 and with 20000
recruits and is designed to have a power of 80%, significance level
of 0.05 to detect a mortality reduction of 20%; a 95% compliance in
the screen group, a 5% contamination rate in the control group
and 10 years follow-up after randomisation. A great deal of
attention was focused on the selection of patients for NELSON in
order to focus on the highest risk groups and thus reduce the cost
of the RCT but retain the power of the study. Potential study
participants were approached by letter with a questionnaire on
their smoking exposure and whether they wished to be included in
the trial. The questionnaire was initially sent to 335441 men and
women aged 50–75 years old. On the basis of this data set the
selection criteria were developed, depending on the duration of
smoking, duration of smoking cessation in ex-smokers, number of
cigarettes smoked per day, and the mean estimated expected lung
Table 3 LDCT RCT lung cancer screening trials
Country
Study name LDCT
Control
arm Study design Selection of participants Report date Publications
The Netherlands and
Belgium
NELSON
8000
a 8000
a LDCT vs no intervention Smokers and ex-smokers with a
history PKS 430 years
Recruitment
completed.
Report 2015
van Iersel et al (2007)
Denmark
NELSON
2000
a 2000
a LDCT vs no intervention Smokers and ex-smokers with a
history PKS 430 years
Recruitment
underway.
Report 2015
Pedersen et al (2002)
Italy
ITALLUNG
1500 1500 LDCT vs no intervention Smokers and ex-smokers PKS
430 years
Report 2005 Picozzi et al (2005)
DANTE 1276 1196 Chest X-ray and sputum cytology
for all patients in year 1. LDCT vs
yearly review
Smokers PKS 420 years Report 2007 Infante et al (2007)
France (pilot)
DepiScan
330 291 LDCT vs chest X-ray Smokers 64% and former
smokers (36%
Report 2006 Blanchon et al (2007)
United States
LSS Feasibility Study
1600 1658 LDCT vs chest X-ray Smokers PKS Report 2005 Gohagan et al (2005)
USA
NLST
26500 26500 LDCT vs chest X-ray Current and ex-smokers PKS Recruitment
completed
http://www.cancer.gov/
NSLT; Ford et al (2003)
LDCT¼low-dose computed tomography; PKS¼pack years.
aPlanned recruitment.
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years 1, 2, and 4, with 10 years of follow-up. The trial has
20000 individuals randomised in equal numbers to LDCT or
‘usual care’.
A number of small trials have been initiated in anticipation of
combination with partner studies or a future meta-analysis. These
include the ItaLung and Dante Trials in Italy (Picozzi et al, 2005;
Infante et al, 2007).
The French randomised pilot study, Depiscan, comparing LDCT
and chest X-ray recently reported its baseline findings (Blanchon
et al, 2007); in this the selection of participants was undertaken by
General Practioners (GPs) and occupational physicians. Eligible
subjects were males and females aged 50–75 years with either a
current or former smoking history of at least 15 cigarettes per day
for 20 years. The screening was undertaken annually for 2 years. The
objective was to enrol 1000 subjects; 765 have been recruited
with 621of these having complete imaging baseline data.
Non-compliance was an important issue in this study and the
recruitment took twice as long as envisaged. Eight lung cancers
were detected in the LDCT arm (2.4%) and one (o1%) in the chest
X-ray arm.
NATIONAL LUNG CANCER SCREENING PROGRAMME
To date, we do not have the results of any randomised trials, which
can provide adequate evidence to justify the instigation of a
National Lung Cancer Screening Programme. The results of the
NLST and NELSON studies are eagerly awaited. The unanswered
question that remains in the United Kingdom is whether either
of these studies will provide adequate information on their own
to justify the implementation of a UK National Screening
Programme? Although the combined US study is large and
should have precise results, the use of an active screening
regime in the control group may raise problems of interpretation.
The NELSON study has adequate power for a substantial benefit
in a high-risk group, but a lower baseline lung cancer mortality
or smaller benefit than anticipated may jeopardise a conclusive
result.
The UK National Screening Committee has determined 22
criteria for the viability, effectiveness, and appropriateness of a
screening programme (http://www.nsc.nhs.uk/uk_nsc/uk_nsc_ind.htm);
20 of which are relevant to LDCT lung cancer screening.
Black et al (2007) have undertaken a systematic review
of the literature to ascertain whether there was evidence for any
clinical effectiveness utilising LDCT for lung cancer screening. This
extremely detailed review was undertaken at the time when there
was a paucity of real data, and thus their conclusions were drawn
from two small trials with very variable results. Not surprisingly,
their conclusion stated that there was insufficient evidence at the
time to support LDCT screening.
The current lack of evidence and the possibility of inconclusive
results from relatively small group of current trials would
suggest that a UK trial would make a valuable contribution to
the research effort worldwide and answer questions particularly
pertinent to the UK health environment. It is a salutary fact
that four decades after the development of this ‘technology’, we
still do not have experimental evidence for or against
the implementation of this screening modality. Lung cancer kills
more individuals in the United Kingdom than any other
malignancy. Our responsibility is not only to determine whether
LDCT screening and treatment of early lesions will decrease
lung cancer mortality compared with a control group without
screening but also to test this against the criteria outlined by
the UK Screening Committee, especially those concerning
cost-effectiveness. A useful aid to cost-effectiveness is the ability
to select a population at sufficiently high risk to give a substantial
harvest of tumours in return for the screening activity. The
Liverpool Lung Project Risk Model provides an opportunity for
this (Field et al, 2007; Cassidy et al, 2008). The risk groups selected
are those for whom the benefits of the screening will outweigh the
likely harms.
The cost-effectiveness of lung cancer LDCT screening has been
estimated by a number of groups, which were reviewed by Black et al
(2006), who found the current estimates difficult to interpret and
certainly not definitive. In response to a request from the UK National
Cancer Research Institute, Whynes (2008) developed a simple and
transparent economic model based on UK costings and the empirical
clinical data are currently available. The UK cost-effectiveness model
used a simple, deterministic approach to the modelling of a screening
regimen. The model required only a limited number of parameters.
The expected mortality gain as a result of screening was estimated by
combining published survival data from screened and unscreened
cohorts with routinely published national mortality figures. Con-
servative costs were estimated where there was uncertainty over
any specific parameter, thus probably resulting in less cost-effective
screening. The incremental cost-effectiveness ratio of a single
CT screen among a high-risk male population was calculated
to be around d14000 per quality-adjusted life year gained, if the
anticipated mortality benefit was indeed observed. Sensitivity analysis
was carried out with a range of differing assumptions, providing a
range of cost-effectiveness ratios as high as d21000 or as low as
around d6000. In the United Kingdom, the National Institute and
Clinical Excellence (NICE) evaluated both clinical and cost-effective-
ness when deciding on recommendations to implement new
interventions. Currently, NICE considered ICERs below d20000 per
QUALY as definitely acceptable and costs up to d30000 as suitable for
consideration.
The approval of any future lung cancer screening trial will
evidently be dependent on costings in line with current political
health economics; however, this defining factor was not applicable
for either breast cancer screening, which was set up after the Forest
Report in 1985 (Gerard et al, 1997), or cervical cancer screening,
which was set up in 1992 (Quinn et al, 1999). The most efficient
way of controlling cost, however, will be to screen those
individuals who are at high risk of developing the disease. There
has been increasing interest in developing methods for individual
risk prediction for lung cancer. Models have been developed for
use within high-risk groups (Bach et al, 2003), and for the general
population (van Klaveren et al, 2002), which rely only on age and
smoking. Epidemiological risk factors usually show poor dis-
crimination between those ‘who do’ and ‘do not’ develop disease
(Wald et al, 1999), but lung cancer is an exception, in that a high
proportion of cases are attributable to one risk factor, smoking.
The predictive accuracy of lung cancer risk models may be further
improved by the addition of other epidemiological risk factors,
including smoking history variables, environmental tobacco
smoke, family history of cancer, prior respiratory disease,
and occupational exposures (dust and asbestos) (Cassidy et al,
2007, 2008; Spitz et al, 2007). The Liverpool Lung Project
(LLP) (Field et al, 2005) has recently developed a method
to calculate absolute risk of lung cancer over a defined period,
based on data from a case–control study of lung cancer in
Liverpool. Significant risk factors in the final model were smoking
duration, family history of lung cancer, history of non-pulmonary
malignant tumour, history of pneumonia, and occupational
exposure to asbestos. These factors were combined with published
age- and sex-specific incidence rates to give absolute probability of
lung cancer development within 5 years. In comparison with
previous lung cancer prediction models, the LLP risk model has
distinctive strengths. First, the predictor variables are all explicitly
defined and can be readily assessed at the time of patient
presentation, and secondly, patients can be assigned to their
appropriate risk class on the basis of information from the initial
history alone. The LLP Risk Model requires rigorous validation in
a separate population.
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Currently, the treatment of advanced lung cancer is inadequate and,
thus, there is an urgent pressure to implement screening pro-
grammes in many countries. In the United Kingdom, no decision
will be made until we have the results of the current international
RCT trials and, hopefully, those from a future UK lung cancer
screening RCT. However, time is not on our side with over 32000
individuals a year dying from lung cancer in the United Kingdom,
and this statistic alone should accelerate progress in reaching a
conclusion concerning the feasibility of lung cancer screening.
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